We previously identified an intermediate β(2)-microglobulin (I-β(2) m), which is an amyloidogenic β(2) m variant, via capillary electrophoresis (CE) and reported hemodialysis (HD)-associated variations in the serum concentrations of each β(2) m component, including that found in the rebound phase. Recent research has indicated that I-β(2) m can bind, via the SO(3)(-) moiety, with glycosaminoglycan or proteoglycan, which are major components of interstitial tissue. Because alterations in I-β(2) m are likely to be important in view of the possible accumulation of amyloidogenic precursor proteins in the interstitial space, we studied the I-β(2) m profile as related to HD. We used CE to determine the I-β(2) m profile both at the start and at the end of HD and during the rebound phase in 12 HD patients. We found both an unfolded β(2) m and a destructured I-β(2) m. More important, two peaks appeared in the rebound phase, one suggesting a refolding and one suggesting an irreversible destruction. Given that the intercompartmental transfer coefficient for β(2) m is 1.0, our results indicated concomitant processes occurring after HD: refolding of the β(2) m conformation and trapping of destructured I-β(2) m in the extravascular space. Because the trapping of destructured I-β(2) m supposedly leads to accumulation of β(2) m in the interstitial space, we have proposed a new concept-a "shuttle" concept-for amyloid formation from β(2) m in the HD setting.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1744-9987.2012.01069.xDOI Listing

Publication Analysis

Top Keywords

rebound phase
12
destructured i-β2
12
i-β2
8
interstitial space
8
i-β2 profile
8
trapping destructured
8
β2
7
capillary electrophoretic
4
electrophoretic profile
4
profile β2-microglobulin
4

Similar Publications

Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice.

Viruses

November 2024

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-361, RJ, Brazil.

Coronavirus disease 2019 (COVID-19) still causes death in elderly and immunocompromised individuals, for whom the sustainability of the vaccine response may be limited. Antiviral treatments, such as remdesivir or molnupiravir, have demonstrated limited clinical efficacy. Nirmatrelvir, an acute respiratory syndrome coronavirus 2 (SARS-CoV-2) major protease inhibitor, is clinically effective but has been associated with viral rebound and antiviral resistance.

View Article and Find Full Text PDF

Background/aim: Despite the donor-exchange program implementation for highly sensitized (HS) patients, no improvement in waiting list in those HS patients with 100% calculated panel reactive of antibodies (cPRA) is observed. Recently, it has been published the treatment with imlifidase in desensitization algorithm. However, there are low-risk strategies to reduce cPRA.

View Article and Find Full Text PDF

Unlocking Drivers of Country-Specific Sensitivities of Atmospheric Greenhouse Gas Accumulation: Preparing for Future Pandemic Management.

Environ Sci Technol

January 2025

Water Research Centre, School of Civil and Environmental Engineering, The University of New South Wales, Sydney, New South Wales 2052, Australia.

The global atmospheric greenhouse gas (GHG) accumulation trajectory has been subjected to fluctuations in the context of the COVID-19 pandemic. Country-level virus prevalence and geography conditions added complexity to understanding atmospheric GHG accumulation sensitivities in terms of the growth rate. Here, extensive data sets were comprehensively analyzed to capture historical and projected fate of atmospheric GHG concentrations.

View Article and Find Full Text PDF

Data on the HIV care cascade demonstrated challenges in achieving Ending the HIV Epidemic (EHE) targets across all 18 EHE focus metropolitan areas, but innovative adherence interventions using point-of-care tenofovir testing and motivational interviewing support care cascade outcomes in Namibia and South Africa, respectively. Data on treatment with long-acting injectable (LAI) antiretroviral therapy (ART) demonstrated high acceptability, retention, and virologic suppression including in groups that were not well represented in clinical trials including persons born female and persons with detectable viral loads. The adjuvanted hepatitis B vaccine appeared to be safe and appeared to be superior to conventional hepatitis B vaccines in persons with HIV (PWH) who were prior nonresponders to the hepatitis B vaccine.

View Article and Find Full Text PDF

HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure.

Antiviral Res

December 2024

Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. Electronic address:

Article Synopsis
  • Serum HBV-RNA (seRNA) is being explored as a marker for measuring the activity of HBV replication in liver cells, and the study investigates its behavior under a specific treatment regimen.
  • The trial involved 40 individuals with chronic HBV who received a combination of tenofovir, pegylated interferon, and a nucleic-acid polymer (NAP) over 48 weeks, revealing unique seRNA patterns in response to the treatments.
  • Results showed that having a lower seRNA half-life was linked to achieving a partial or functional cure, suggesting that faster inactivation of cccDNA – the genetic material driving the virus – might lead to better treatment outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!